Shopping Cart 0
Cart Subtotal
USD 0

Advaxis Inc (ADXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen, and lessen factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Under the Lm Technology platform, the company has four immunotherapy candidates in development, Axalimogene filolisbac (AXAL) in Human Papilloma Virus (HPV)-associated cancers; Neoantigen Therapy (ADXS-NEO); ADXS-PSA in prostate cancer; and ADXS-HER2 in HER2-expressing solid tumors. Advaxis is headquartered in Princeton, New Jersey, the US.

Advaxis Inc (ADXS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advaxis Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Advaxis and Bristol-Myers Squibb Enter into Agreement 13

Amgen Forms Partnership with Advaxis 14

Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16

Advaxis Enters into Research Agreement with Sorrento Therapeutics 17

Advaxis Enters into Agreement with Merck 18

Advaxis Enters into Agreement with MedImmune 19

Licensing Agreements 20

OS Therapies Enters into Licensing Agreement with Advaxis 20

Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21

Knight Therapeutics Enters into Licensing Agreement with Advaxis 22

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23

Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26

Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28

Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30

Equity Offering 31

Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31

Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33

Advaxis Prices Public Offering of Shares for USD20 Million 34

Advaxis Raises USD30.3 Million in Private Placement of Shares 36

Advaxis Raises USD25 Million in Private Placement of Shares 37

Advaxis Raises USD61.2 Million in Public Offering of Shares 39

Advaxis Raises USD23 Million in Private Placement of Common Stock 41

Advaxis Raises USD17 Million in Private Placement of Shares 43

Advaxis Raises USD14 Million in Public Offering Of Shares 45

Advaxis Completes Public Offering Of Shares For USD 26.5 Million 46

Advaxis Announces Private Placement Of Common Stock For USD 10 Million 47

Advaxis Inc-Key Competitors 48

Advaxis Inc-Key Employees 49

Advaxis Inc-Locations And Subsidiaries 50

Head Office 50

Recent Developments 51

Financial Announcements 51

Sep 10, 2018: Advaxis reports fiscal 2018 third quarter financial results 51

Jun 07, 2018: Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results 53

Mar 12, 2018: Advaxis Announces Q1 Fiscal 2018 Financial Results 55

Dec 20, 2017: Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update 57

Sep 11, 2017: Advaxis Reports Business Update and Third Quarter 2017 Results 59

Corporate Communications 61

Jun 06, 2018: Advaxis Appoints Molly Henderson as Chief Financial Officer 61

Jul 06, 2017: Advaxis Announces Change in Leadership 62

Apr 19, 2017: Advaxis Appoints Anthony Lombardo as Chief Business Officer 63

Product News 64

Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials 64

03/26/2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 65

03/12/2018: Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's IMFINZI (Durvalumab) 66

01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies 67

01/25/2017: New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported 68

Product Approvals 69

Jul 13, 2018: Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab 69

Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union 70

Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 71

Clinical Trials 72

Apr 17, 2018: Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting 72

Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer 73

Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 74

Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 75

May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 76

Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 77

Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer 78

Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 80

Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer 81

Other Significant Developments 82

Jul 10, 2018: Advaxis Provides Update on MAA Filing and ADXS-HOT Program 82

Jun 13, 2017: Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day 83

Jan 09, 2017: Advaxis Provides 2017 Business Outlook 86

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Advaxis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advaxis and Bristol-Myers Squibb Enter into Agreement 13

Amgen Forms Partnership with Advaxis 14

Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16

Advaxis Enters into Research Agreement with Sorrento Therapeutics 17

Advaxis Enters into Agreement with Merck 18

Advaxis Enters into Agreement with MedImmune 19

OS Therapies Enters into Licensing Agreement with Advaxis 20

Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21

Knight Therapeutics Enters into Licensing Agreement with Advaxis 22

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23

Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26

Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28

Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30

Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31

Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33

Advaxis Prices Public Offering of Shares for USD20 Million 34

Advaxis Raises USD30.3 Million in Private Placement of Shares 36

Advaxis Raises USD25 Million in Private Placement of Shares 37

Advaxis Raises USD61.2 Million in Public Offering of Shares 39

Advaxis Raises USD23 Million in Private Placement of Common Stock 41

Advaxis Raises USD17 Million in Private Placement of Shares 43

Advaxis Raises USD14 Million in Public Offering Of Shares 45

Advaxis Completes Public Offering Of Shares For USD 26.5 Million 46

Advaxis Announces Private Placement Of Common Stock For USD 10 Million 47

Advaxis Inc, Key Competitors 48

Advaxis Inc, Key Employees 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Advaxis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen, and lessen factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Under the Lm Technology platform, the company has four immunotherapy candidates in development, Axalimogene filolisbac (AXAL) in Human Papilloma Virus (HPV)-associated cancers; Neoantigen Therapy (ADXS-NEO); ADXS-PSA in prostate cancer; and ADXS-HER2 in HER2-expressing solid tumors. Advaxis is headquartered in Princeton, New Jersey, the US.

Advaxis Inc (ADXS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advaxis Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Advaxis and Bristol-Myers Squibb Enter into Agreement 13

Amgen Forms Partnership with Advaxis 14

Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16

Advaxis Enters into Research Agreement with Sorrento Therapeutics 17

Advaxis Enters into Agreement with Merck 18

Advaxis Enters into Agreement with MedImmune 19

Licensing Agreements 20

OS Therapies Enters into Licensing Agreement with Advaxis 20

Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21

Knight Therapeutics Enters into Licensing Agreement with Advaxis 22

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23

Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26

Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28

Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30

Equity Offering 31

Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31

Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33

Advaxis Prices Public Offering of Shares for USD20 Million 34

Advaxis Raises USD30.3 Million in Private Placement of Shares 36

Advaxis Raises USD25 Million in Private Placement of Shares 37

Advaxis Raises USD61.2 Million in Public Offering of Shares 39

Advaxis Raises USD23 Million in Private Placement of Common Stock 41

Advaxis Raises USD17 Million in Private Placement of Shares 43

Advaxis Raises USD14 Million in Public Offering Of Shares 45

Advaxis Completes Public Offering Of Shares For USD 26.5 Million 46

Advaxis Announces Private Placement Of Common Stock For USD 10 Million 47

Advaxis Inc-Key Competitors 48

Advaxis Inc-Key Employees 49

Advaxis Inc-Locations And Subsidiaries 50

Head Office 50

Recent Developments 51

Financial Announcements 51

Sep 10, 2018: Advaxis reports fiscal 2018 third quarter financial results 51

Jun 07, 2018: Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results 53

Mar 12, 2018: Advaxis Announces Q1 Fiscal 2018 Financial Results 55

Dec 20, 2017: Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update 57

Sep 11, 2017: Advaxis Reports Business Update and Third Quarter 2017 Results 59

Corporate Communications 61

Jun 06, 2018: Advaxis Appoints Molly Henderson as Chief Financial Officer 61

Jul 06, 2017: Advaxis Announces Change in Leadership 62

Apr 19, 2017: Advaxis Appoints Anthony Lombardo as Chief Business Officer 63

Product News 64

Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials 64

03/26/2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 65

03/12/2018: Advaxis Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's IMFINZI (Durvalumab) 66

01/29/2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies 67

01/25/2017: New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported 68

Product Approvals 69

Jul 13, 2018: Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab 69

Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union 70

Mar 23, 2017: EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer 71

Clinical Trials 72

Apr 17, 2018: Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting 72

Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer 73

Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders 74

Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 75

May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 76

Mar 27, 2017: Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac 77

Mar 15, 2017: Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO's Annual Meeting on Women's Cancer 78

Feb 06, 2017: Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer 80

Jan 30, 2017: GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer 81

Other Significant Developments 82

Jul 10, 2018: Advaxis Provides Update on MAA Filing and ADXS-HOT Program 82

Jun 13, 2017: Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day 83

Jan 09, 2017: Advaxis Provides 2017 Business Outlook 86

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Advaxis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Advaxis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Advaxis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Advaxis Inc, Medical Devices Deals, 2012 to YTD 2018 10

Advaxis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Advaxis and Bristol-Myers Squibb Enter into Agreement 13

Amgen Forms Partnership with Advaxis 14

Advaxis Enters into Co-Development Agreement with Especificos Stendhal 15

Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 16

Advaxis Enters into Research Agreement with Sorrento Therapeutics 17

Advaxis Enters into Agreement with Merck 18

Advaxis Enters into Agreement with MedImmune 19

OS Therapies Enters into Licensing Agreement with Advaxis 20

Sellas Life Sciences Enters into Licensing Agreement with Advaxis 21

Knight Therapeutics Enters into Licensing Agreement with Advaxis 22

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 23

Aratana Therapeutics Enters into Licensing Agreement with Advaxis 24

Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 26

Advaxis Enters Into Licensing Agreement With Global BioPharma For ADXS-HPV 28

Advaxis Enters Into Agreement With FusionVax To License ADXS-HPV In Asia 30

Advaxis Raises USD20 Million in Public Offering of Shares and Warrants 31

Advaxis Plans to Raise up to USD250 in Public Offering of Securities 33

Advaxis Prices Public Offering of Shares for USD20 Million 34

Advaxis Raises USD30.3 Million in Private Placement of Shares 36

Advaxis Raises USD25 Million in Private Placement of Shares 37

Advaxis Raises USD61.2 Million in Public Offering of Shares 39

Advaxis Raises USD23 Million in Private Placement of Common Stock 41

Advaxis Raises USD17 Million in Private Placement of Shares 43

Advaxis Raises USD14 Million in Public Offering Of Shares 45

Advaxis Completes Public Offering Of Shares For USD 26.5 Million 46

Advaxis Announces Private Placement Of Common Stock For USD 10 Million 47

Advaxis Inc, Key Competitors 48

Advaxis Inc, Key Employees 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Advaxis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.